查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1871296

多癌種早期檢測（MCED）測試市場機會、成長促進因素、產業趨勢分析及2025-2034年預測

Multi Cancer Early Detection (MCED) Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球多癌症早期檢測 (MCED) 測試市場價值為 15 億美元，預計到 2034 年將以 14.1% 的複合年成長率成長至 58 億美元。

多重癌種早期檢測（MCED）測試市場 - IMG1

受全球癌症發病率上升、對早期診斷解決方案的需求不斷成長以及分子診斷技術快速發展的推動，市場正呈現強勁成長動能。多組學早期診斷（MCED）檢測利用液體活體組織切片和新一代定序（NGS）等方法，僅需一份血液樣本即可檢測多種癌症類型，從而重新定義了傳統的篩檢方法。這些檢測使臨床醫生能夠更早、更全面地識別癌症，並正在改變腫瘤學領域。這些公司透過不斷改進液體活體組織切片技術、整合多組學資料以及人工智慧驅動的分析，提升檢測的精確度和臨床應用性，從而為多種癌症類型開發出高靈敏度和高特異性的診斷解決方案。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 15億美元
預測值 58億美元
複合年成長率 14.1%

基因組檢測、實驗室自建檢測 (LDT) 及其他相關細分市場預計到 2034 年將以 14% 的複合年成長率成長。此細分市場佔據主導地位，原因在於其商業化進程較早、能夠靈活地針對特定突變，以及醫療機構和研究機構的廣泛採用。這些檢測方法分析基因突變、甲基化模式和其他分子特徵，從而支持多種癌症的個人化篩檢。

預計到2034年，醫院領域的市場規模將達到29億美元。醫院在管理複雜的診斷流程和多學科診療方面具有優勢，腫瘤科醫生、病理學家和遺傳學家等專家通力合作，共同解讀檢測結果。這種團隊協作能夠確保早期精準檢測，並為治療方案的製定提供切實可行的指導。預防性醫療保健措施也進一步鞏固了該領域的重要性。

北美多癌種早期檢測 (MCED) 市場受益於人們對預防性醫療保健的高度重視、對精準腫瘤學的大力投入以及液體活體組織切片和基因panel篩檢的早期應用。該地區先進的醫療保健基礎設施和對早期診斷的重視，持續推動醫院、實驗室和健康管理項目對相關產品的需求。

多重癌種早期檢測 (MCED) 市場的主要企業包括安派生物醫學科技、燃石生物、EarlyDiagnostics、Elypta、Freenome Holdings、EXACT SCIENCES CORPORATION、Genecast Biotechnology、廣州安科德醫療、GUARDANT HEALTH、Harbinger Health、GRAIL、Micron、SWelics 和 Sraemics。市場領導者透過投資先進的診斷技術（包括人工智慧驅動的分析和多組學整合）來增強自身實力，從而提高檢測的準確性。他們積極拓展臨床合作，加強與研究機構的合作，並專注於獲得監管部門的批准，以提高檢測的可近性。液體活體組織切片和基因panel檢測的持續創新，以及早期商業化策略，使企業能夠開拓新市場。此外，他們還優先考慮向醫護人員和患者普及MCED檢測的益處，投資於預防性醫療保健活動，並最佳化分銷管道，以確保在醫院、實驗室和健康管理項目中廣泛應用。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

  • 產業生態系分析
    • 供應商格局
    • 影響價值鏈的因素
  • 產業影響因素
    • 成長促進因素
      • 癌症發生率不斷上升
      • 癌症檢出率高，加上對有效癌症檢測工具的需求不斷成長，使得人們更需要這些工具。
      • 資料分析和人工智慧 (AI) 在癌症篩檢中的應用
    • 產業陷阱與挑戰
      • 多種癌症篩檢測試費用高昂
    • 市場機遇
      • 拓展至預防保健及人口健康項目
  • 成長潛力分析
  • 監管環境
  • 技術格局
    • 當前技術趨勢
    • 新興技術
  • 未來市場趨勢
  • 2024年定價分析
  • 專利分析
  • 報銷方案
  • 波特的分析
  • PESTEL 分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估算與預測：依類型分類，2021-2034年

  • 主要趨勢
  • 基因檢測、LDT 等
  • 液體活體組織切片

第6章：市場估算與預測：依最終用途分類，2021-2034年

  • 主要趨勢
  • 醫院
  • 診斷實驗室
  • 其他最終用途

第7章：市場估計與預測：依地區分類，2021-2034年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第8章：公司簡介

  • AnPac Bio-Medical Science
  • Burning Rock Biotech
  • EarlyDiagnostics
  • Elypta
  • EXACT SCIENCES CORPORATION
  • Freenome Holdings
  • Genecast Biotechnology
  • Guangzhou AnchorDx Medical
  • GUARDANT HEALTH
  • Harbinger Health
  • GRAIL
  • Micronoma
  • SeekIn
  • Singlera Genomics
簡介目錄
Product Code: 11171

The Global Multi Cancer Early Detection (MCED) Test Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 14.1% to reach USD 5.8 billion by 2034.

Multi Cancer Early Detection (MCED) Test Market - IMG1

The market is witnessing strong momentum, fueled by the rising prevalence of cancer worldwide, increasing demand for early diagnostic solutions, and rapid progress in molecular diagnostic technologies. MCED tests, leveraging methods such as liquid biopsy and next-generation sequencing (NGS), enable the detection of multiple cancer types from a single blood sample, redefining traditional screening approaches. These tests are transforming oncology by allowing clinicians to identify cancers earlier and more comprehensively. These companies enhance test precision and clinical applicability through continuous advancements in liquid biopsy techniques, integration of multi-omics data, and AI-driven analytics, creating highly sensitive and specific diagnostic solutions for a wide spectrum of cancer types.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.5 Billion
Forecast Value$5.8 Billion
CAGR14.1%

The gene panel, laboratory-developed test (LDT), and other related segments are projected to grow at a CAGR of 14% through 2034. This segment dominates the market due to early commercialization, flexibility in targeting specific mutations, and adoption by healthcare providers and research institutions. These tests analyze genetic mutations, methylation patterns, and other molecular signatures, supporting personalized screening approaches across multiple cancers.

The hospitals segment is projected to reach USD 2.9 billion by 2034. Hospitals are preferred for managing complex diagnostic workflows and multidisciplinary care, with oncologists, pathologists, and geneticists collaborating to interpret test results. This teamwork ensures accurate early detection and actionable insights for treatment planning. Preventive healthcare initiatives further reinforce the segment's prominence.

North America Multi Cancer Early Detection (MCED) Test Market is supported by high awareness of preventive healthcare, robust investment in precision oncology, and early adoption of liquid biopsy and gene panel-based screening. The region's advanced healthcare infrastructure and focus on early diagnosis sustain demand across hospitals, laboratories, and wellness programs.

Key companies in the Multi Cancer Early Detection (MCED) Test Market include AnPac Bio-Medical Science, Burning Rock Biotech, EarlyDiagnostics, Elypta, Freenome Holdings, EXACT SCIENCES CORPORATION, Genecast Biotechnology, Guangzhou AnchorDx Medical, GUARDANT HEALTH, Harbinger Health, GRAIL, Micronoma, SeekIn, and Singlera Genomics. Market leaders strengthen their presence by investing in advanced diagnostic technologies, including AI-driven analysis and multi-omics integration, to improve test accuracy. They actively expand clinical collaborations, enhance partnerships with research institutions, and focus on regulatory approvals to increase accessibility. Continuous innovation in liquid biopsy and gene panel testing, alongside early commercialization strategies, allows companies to capture new markets. Additionally, they prioritize educating healthcare providers and patients about the benefits of MCED testing, invest in preventive healthcare campaigns, and optimize distribution channels to ensure wide availability across hospitals, laboratories, and wellness programs.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Type trends
    • 2.2.3 End Use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Factors affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of cancer
      • 3.2.1.2 High cancer detection rate coupled with growing demand for effective cancer tools
      • 3.2.1.3 Advancements in data analytics and artificial intelligence (AI) utilized in cancer screening
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of multi-cancer screening tests
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion into preventive care and population health programs
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Future market trends
  • 3.7 Pricing analysis, 2024
  • 3.8 Patent analysis
  • 3.9 Reimbursement scenario
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Gene panel, LDT and others
  • 5.3 Liquid biopsy

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Diagnostic laboratories
  • 6.4 Other End use

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 India
    • 7.4.3 Japan
    • 7.4.4 Australia
    • 7.4.5 South Korea
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE

Chapter 8 Company Profiles

  • 8.1 AnPac Bio-Medical Science
  • 8.2 Burning Rock Biotech
  • 8.3 EarlyDiagnostics
  • 8.4 Elypta
  • 8.5 EXACT SCIENCES CORPORATION
  • 8.6 Freenome Holdings
  • 8.7 Genecast Biotechnology
  • 8.8 Guangzhou AnchorDx Medical
  • 8.9 GUARDANT HEALTH
  • 8.10 Harbinger Health
  • 8.11 GRAIL
  • 8.12 Micronoma
  • 8.13 SeekIn
  • 8.14 Singlera Genomics